OnKure Therapeutics, Inc. (OKUR) Stock Forecast & Price Target
OnKure Therapeutics, Inc. · NASDAQ
$3.41-0.17 (-4.75%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering OnKure Therapeutics, Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $14.00 to $21.00, a moderate spread. The average target of $17.50 sits 413% above the current $3.41. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.43 next quarter toward $-1.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to OnKure Therapeutics, Inc.
As of Sep, 2 of 2 firms rate OKUR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
OKUR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.67 – $-0.30 · 4 analysts · -56% YoY
Next period, 4 analysts expect OnKure Therapeutics, Inc. to earn $-0.43 a share (range $-0.67 – $-0.30), versus $-0.99 a year earlier. Full-year consensus is $-1.83, growing to $-1.53 the year after.
REVENUE · NEXT QUARTER
$125.0K
Range $0 – $500.0K · 4 analysts
Revenue is expected to reach $125.0K (range $0 – $500.0K). Full-year consensus is $250.0K, rising to $666.7K next year.
Top analysts covering OnKure Therapeutics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OKUR.
#1
Andrew Berens
Leerink Partners · Rank #121
Buy
$33.00+867.7% to target
Overall win rate
56%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$21.00+515.8% to target
Overall win rate
41%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #307
Buy
$14.00+310.6% to target
Overall win rate
37%
+ Follow
#4
JM
Jonathan Miller
Evercore ISI
Buy
No targeton OKUR
Coverage
—
+ Follow
#5
MB
Matt Biegler
Oppenheimer
Buy
$30.00+779.8% to target
Coverage
—
+ Follow
OKUR stock forecast FAQ
What is OKUR's average 12-month price target?+
The 2 analysts with a live target average $17.50 for OnKure Therapeutics, Inc. over the next 12 months, ranging from a $21.00 high to a $14.00 low.
Is OKUR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for OKUR?+
The Street-high target is $21.00 (HC Wainwright & Co.), and the Street-low is $14.00 (Oppenheimer). The average of all 2 active targets is $17.50.
How many Wall Street analysts cover OKUR?+
2 analysts have an active rating on OnKure Therapeutics, Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering OKUR?+
Among analysts who currently cover OKUR, Andrew Berens of Leerink Partners has the strongest overall Quantellect track record (Rank #121). Their current call is Buy with a $33.00 target.
What is OnKure Therapeutics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.67 – $-0.30) across 4 analysts. Full-year EPS is projected at $-1.83, rising to $-1.53 the following year.
How much revenue is OnKure Therapeutics, Inc. expected to report next quarter?+
Consensus revenue is $125.0K (range $0 – $500.0K). Full-year revenue is projected at $250.0K, growing to $666.7K next year.
Have analysts been upgrading or downgrading OKUR lately?+
As of Sep, 2 of 2 firms rate OKUR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OKUR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
